<DOC>
	<DOCNO>NCT02120300</DOCNO>
	<brief_summary>The primary objective study evaluate antiviral efficacy , safety , tolerability treatment ledipasvir/sofosbuvir ( LDV/SOF ) fixed-dose combination ( FDC ) participant genotypes 1 4 hepatitis C virus ( HCV ) infection sofosbuvir ( SOF ) plus ribavirin ( RBV ) participant genotypes 2 3 HCV infection . Participants inherit bleed disorder chronic HCV infection ( either monoinfected HIV-1/HCV coinfected ) enrol .</brief_summary>
	<brief_title>Efficacy Safety Ledipasvir/Sofosbuvir Fixed-Dose Combination Sofosbuvir + Ribavirin Subjects With Chronic Hepatitis C Virus ( HCV ) Inherited Bleeding Disorders</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Hemophilia A , B C , Von Willebrand 's disease Chronic genotype 1 , 2 , 3 4 HCV infection HCV RNA â‰¥ 1000 IU/mL screen Use protocol specify method ( ) contraception female childbearing potential sexually active male Screening laboratory value within defined threshold For HIV1/HCV coinfected individual : Suppressed HIV1 RNA antiretroviral ( ARV ) regimen least 6 month prior screen Stable protocolapproved ARV regimen &gt; 8 week prior screen CD4 Tcell count &gt; 200 cells/mm^3 screen Clinicallysignificant illness ( HCV , inherit bleed disorder HIV1 ) major medical disorder may interfere subject treatment , assessment compliance protocol Current prior history follow : Hepatic decompensation Chronic liver disease nonHCV etiology Hepatocellular carcinoma ( HCC ) Infection hepatitis B virus ( HBV ) Pregnant nursing female Prior treatment inhibitor nonstructural protein 5A ( NS5A ) NS5B polymerase Chronic use systemically administer immunosuppressive agent For HIV1/HCV coinfected individual : Opportunistic infection within 6 month prior screen Active , serious infection ( HIV1 HCV ) require parental antibiotic , antiviral antifungal within 30 day prior baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>